Freitag Gregory Gene 4
4 · Axogen, Inc. · Filed Jun 5, 2023
Insider Transaction Report
Form 4
Axogen, Inc.AXGN
Freitag Gregory Gene
DirectorCFO
Transactions
- Sale
Common Stock
2023-06-01$8.65/sh−12,500$108,125→ 319,615 total - Exercise/Conversion
Restricted Stock Units
2023-06-01−6,459→ 0 total→ Common Stock (6,459 underlying) - Sale
Common Stock
2023-06-01$8.74/sh−29,480$257,655→ 290,135 total - Exercise/Conversion
Common Stock
2023-06-01+6,459→ 296,594 total
Footnotes (5)
- [F1]The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.57 to $8.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.83 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]This reflects the number of restricted stock units that vested on June 1, 2023.
- [F4]Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
- [F5]Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date.